| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Pemazyre | |
| 3 | Generic | pemigatinib | |
| 4 | Indication | cholangiocarcinoma approved; glioblastoma | |
| 5 | MOA | FGFR1/FGFR2/FGFR3 inhibitor | |
| 6 | Regulatory | China approval | |
| 7 | Clinical Trials | ||
| 8 | Phase II "FIGHT-209" glioblastoma | ||
| 9 | |||
| 10 | Phase II "FIGHT-210" NSCLC | ||
| 11 | |||
| 12 | Phase III "FIGHT-302" cholangiocarcinoma | ||
| 13 | |||
| 14 | Phase II "FIGHT-203" myeloid/lymphoid |